Febuxostat in Gout: Serum Urate Response in Uric Acid Overproducers and Underexcretors D.S. Goldfarb, P.A. MacDonald, B. Hunt, L. Gunawardhana 1385

Consistency of Knee Pain and Risk of Knee Replacement: The Multicenter OA Study

Bisphosphonate-associated Osteonecrosis of the Jaw in Ontario: A Survey of Oral and Maxillofacial Surgeons
A.A. Khan, L.P. Rios, G.K.B. Sandor, et al 1396

Long-term Therapeutic Response to Milnacipran Treatment for FM: A European 1-Year Extension Study Following a 3-Month Study J.C. Branco, P. Cherin, A. Montagne, A. Bouroubi, on behalf of the Multinational Coordinator Study Group 1403

Specialized Rheumatology Nurse Substitutes for Rheumatologists in the Diagnostic Process of FM: A Cost-Consequence Analysis and RCT

Pediatric Rheumatology

Heterotopic Ossification of the TMJ in JIA
S. Ringold, M. Thapa, E.A. Shaw, C.A. Wallace 1423

MBL Expression Genotype in Pediatric-onset SLE: Associations with Susceptibility to Renal Disease and Protection Against Infections Y-C. Tsai, K-W. Yeh, T-C. Yao, Y-L. Huang, M-L. Ku, J-L. Huang 1429

Safety and Efficacy of Rituximab in Severe Juvenile DM: Results from 9 Patients from the French Autoimmunity and Rituximab Registry B. Bader-Meunier, H. Decaluwe, C. Barnerias, et al for the Club Rhumatismes et Inflammation 1436

Development of IBD in Patients with JIA Treated with Etanercept T.D. van Dijken, S.J. Vastert, V.M. Gerloni, et al 1441

Images in Rheumatology

Fluorescence Optical Imaging of Juvenile Arthritis
S.G. Werner, H-E. Langer, G. Horneff 1447

OMERACT 10

10th International Consensus Conference on Outcome Measures in Rheumatology Kota Kinabalu, Borneo - May 4-8, 2010
Introduction 1448

Disease-specific Outcomes


Tophus Measurement as an Outcome Measure for Clinical Trials of Chronic Gout: Progress and Research Priorities N. Dalbeth, F.M. McQueen, J.A. Singh, et al 1458

Serum Urate in Chronic Gout — Will It Be the First Validated Soluble Biomarker in Rheumatology? L.K. Stamp, P.P. Khanna, N. Dalbeth, et al 1462


Toward Development of a FM Responder Index and Disease Activity Score: OMERACT Module Update P.J., Mease, D.J. Clauw, R. Christensen, et al and the OMERACT Fibromyalgia Working Group 1487


Endorsement of Definitions of Disease Activity States and Improvement Scores for the AS Disease Activity Score: Results from OMERACT 10 P.M.M.C. Machado, R.B.M. Landewé, D.M. van der Heijde 1502


Developing Disease Activity and Response Criteria in CTD-related ILD L.A. Saketkoo, E.L. Matteson, K.K. Brown, J.R. Seibold, V. Strand; for the Connective Tissue Disease-related Interstitial Lung Disease Special Interest Group 1514

Correspondence

Where in the World is Oral Triamcinolone? L. Roger 1519
Reply R. Aiten 1519

Lupus Related Longitudinal Myelitis D.M. Wingerchuk, B.G. Weimshenker 1520
Reply P. Zotos 1521


Who Discovered the ESR? A. Grzybowski, J.J. Sak 1521
Reply E.L. Matteson, C.S. Crowson 1523

Letters


Acute Presentation of Tophaceous Myelopathy E. Levin, K. Hurth, R. Joshi, R. Brassington 1525

AS Refractory to TNF Blockade Responds to Tocilizumab J-D. Cohen, R. Ferreira, C. Jorgensen 1527

Positive C-ANCA with PR3 Specificity Glomerulonephritis in a Patient with Subacute Bacterial Endocarditis M. Uh, I.A. McCormick, J.T. Kelsall 1528

Primary Aldosteronism Simulating Polymyositis Y-C. Tang, S-K. Wang, W-L. Yuan 1529

Corrections

Intraarticular Botulinum Toxin A for Refractory Painful Total Knee Arthroplasty: A Randomized Controlled Trial J.A. Singh, M.L. Mahowald, S. Noorbalaouchi 1534


Meetings in Rheumatology